Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10462224" target="_blank" >RIV/00064203:_____/23:10462224 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10462224
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=62faRUWCaA</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.22.01760" target="_blank" >10.1200/JCO.22.01760</a>
Alternative languages
Result language
angličtina
Original language name
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial
Original language description
PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m(2) every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS +- SE) and overall survival (OS +- SE) rates were 75.2% +- 0.6% and 82.6% +- 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% +- 1.4% and 94.7% +- 1.1%; IR (n = 4,111), 77.9% +- 0.7% and 85.7% +- 0.6%; and HR (n = 1,452), 60.8% +- 1.5% and 68.4% +- 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% +- 1.2% and 72.8% +- 1.2%, respectively (P = .55), while those in patients receiving MTX doses of 2 g/m(2) (n = 1,056) and MTX 5 g/m(2) (n = 1,027) were 78.8% +- 1.4% and 78.9% +- 1.4%, respectively (P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m(2) was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
1527-7755
Volume of the periodical
41
Issue of the periodical within the volume
19
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
3499-3511
UT code for WoS article
001037224100009
EID of the result in the Scopus database
2-s2.0-85161436569